학술논문
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants
Document Type
article
Author
Taru A. Muranen; Anna Morra; Sofia Khan; Daniel R. Barnes; Manjeet K. Bolla; Joe Dennis; Renske Keeman; Goska Leslie; Michael T. Parsons; Qin Wang; Thomas U. Ahearn; Kristiina Aittomäki; Irene L. Andrulis; Banu K. Arun; Sabine Behrens; Katarzyna Bialkowska; Stig E. Bojesen; Nicola J. Camp; Jenny Chang-Claude; Kamila Czene; Peter Devilee; HEBON investigators; Susan M. Domchek; Alison M. Dunning; Christoph Engel; D. Gareth Evans; Manuela Gago-Dominguez; Montserrat García-Closas; Anne-Marie Gerdes; Gord Glendon; Pascal Guénel; Eric Hahnen; Ute Hamann; Helen Hanson; Maartje J. Hooning; Reiner Hoppe; Louise Izatt; Anna Jakubowska; Paul A. James; Vessela N. Kristensen; Fiona Lalloo; Geoffrey J. Lindeman; Arto Mannermaa; Sara Margolin; Susan L. Neuhausen; William G. Newman; Paolo Peterlongo; Kelly-Anne Phillips; Miquel Angel Pujana; Johanna Rantala; Karina Rønlund; Emmanouil Saloustros; Rita K. Schmutzler; Andreas Schneeweiss; Christian F. Singer; Maija Suvanto; Yen Yen Tan; Manuel R. Teixeira; Mads Thomassen; Marc Tischkowitz; Vishakha Tripathi; Barbara Wappenschmidt; Emily Zhao; Douglas F. Easton; Antonis C. Antoniou; Georgia Chenevix-Trench; Paul D. P. Pharoah; Marjanka K. Schmidt; Carl Blomqvist; Heli Nevanlinna
Source
npj Breast Cancer, Vol 9, Iss 1, Pp 1-15 (2023)
Subject
Language
English
ISSN
2374-4677
Abstract
Abstract We assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the Breast Cancer Association Consortium (BCAC). PREDICT for estrogen receptor (ER)-negative breast cancer had modest discrimination for BRCA1 carrier patients overall (Gönen & Heller unbiased concordance 0.65 in CIMBA, 0.64 in BCAC), but it distinguished clearly the high-mortality group from lower risk categories. In an analysis of low to high risk categories by PREDICT score percentiles, the observed mortality was consistently lower than the expected mortality, but the confidence intervals always included the calibration slope. Altogether, our results encourage the use of the PREDICT ER-negative model in management of breast cancer patients with germline BRCA1 variants. For the PREDICT ER-positive model, the discrimination was slightly lower in BRCA2 variant carriers (concordance 0.60 in CIMBA, 0.65 in BCAC). Especially, inclusion of the tumor grade distorted the prognostic estimates. The breast cancer mortality of BRCA2 carriers was underestimated at the low end of the PREDICT score distribution, whereas at the high end, the mortality was overestimated. These data suggest that BRCA2 status should also be taken into consideration with tumor characteristics, when estimating the prognosis of ER-positive breast cancer patients.